- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Optimal Perampanel Blood Level Based on the Correlation between The Efficacy and Blood Concentration in Patients with Focal Epilepsy
-
- Iwasaki Toshiyuki
- Department of Pediatrics, Shonantobu General Hospital Department of Pediatrics, St. Marianna University School of Medicine
Bibliographic Information
- Other Title
-
- 焦点てんかん患者におけるペランパネル内服治療の有効性と血中濃度との相関ならびに至適血中濃度の検討
Search this article
Description
<p>Objective: To evaluate the efficacy of perampanel (PER) over a period of 2 years and the usefulness of measuring blood levels during follow-up for patients with focal epilepsy.<br/>Methods: A total of 46 patients with focal epilepsy (mean age: 24.7±9.3 years) were identified from medical records and their peak blood PER levels were measured. Of the 46 patients, 18 used enzyme inducers (carbamazepine, phenobarbital, phenytoin and topiramate) in combination with PER. Blood PER levels were measured immediately after reaching the PER maintenance dosage and 6 months, 1, 1.5, and 2 years later. The efficacy of PER was evaluated at the same time points as the blood sampling to determine the seizure reduction rate. The cases were then classified as effective (mean seizure reduction rates ≧50%) or ineffective (<50%).<br/>Results: The dosage and blood PER levels showed a positive correlation in cases of combination use without an inducer (r=0.388). However, no correlations were seen in all patients or in cases of combination use with an inducer (r=0.247, 0.326, respectively). In several groups, there was no positive correlations were seen between blood PER levels and efficacy. In all patients and cases of combination use with an inducer, significant differences were seen in the blood PER levels of effective vs. ineffective cases (p=0.041, 0.007, respectively). The optimal range was 500–530 ng/mL based on the mean and standard deviation in the effective cases. In the case of combination use, the range was 420–600 ng/mL.<br/>Conclusion: We recommend an optimal range of PER as a therapeutic target as 500–600 ng/mL. Because this range is the common range of all patients and cases of combination use with an inducer.</p>
Journal
-
- The St. Marianna Medical Journal
-
The St. Marianna Medical Journal 49 (4), 127-134, 2022
St. Marianna University Society of Medical Science
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390010292645193216
-
- ISSN
- 21890285
- 03872289
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed